Creating a culture that focuses on the behaviours required to achieve the results desired, has been the root cause of Releaf’s success in the UK’s medical cannabis sector – a sector that has stagnated since medical cannabis became legal in 2018.
The medical cannabis sector in the UK is navigating a dual imperative: ensuring rigorous compliance with regulatory standards while delivering compassionate care to patients in need. For UK medical cannabis clinic Releaf, these two objectives are not only complementary but also foundational to its operations.
Business of Cannabis recently sat down with Releaf’s Chief Operating Officer, Graham Woodward, a trained psychiatric nurse and former clinical director and CQC Specialist Advisor, to discuss the impact of the lack of access to training how clinics such as Releaf are working to change it.
Since the UK legalisation of CBPMs in 2018, the sector has faced slow adoption due to ineffective patient outreach, inconsistent supply chains and variable quality control from other providers.
Approaching the sixth anniversary of the legalisation of medical cannabis in the UK, private prescriptions are on the rise, but
SOMAÍ Pharmaceuticals is proud to announce a strategic partnership with Releaf, the UK’s fastest-growing medical cannabis clinic, to bring innovative
Over half of the UK’s population could benefit from medical cannabis, but the lack of awareness means millions of potential
Written for Business of Cannabis by Releaf. General Practitioners (GPs) are on the frontline of healthcare in the UK, and
Medical cannabis cultivator Glass Pharms has officially delivered its first crop to the first UK-based clinic, marking the first time
Written for Business of Cannabis by Releaf. The UK moved to legalise medical cannabis in 2018, but while the market
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
